BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 25361007)

  • 1. BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications.
    Oikonomou E; Koustas E; Goulielmaki M; Pintzas A
    Oncotarget; 2014 Dec; 5(23):11752-77. PubMed ID: 25361007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.
    Zhao Y; Yu H; Ida CM; Halling KC; Kipp BR; Geiersbach K; Rumilla KM; Gupta S; Lin MT; Zheng G
    JAMA Netw Open; 2021 Jan; 4(1):e2035479. PubMed ID: 33507258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.
    Janku F; Lee JJ; Tsimberidou AM; Hong DS; Naing A; Falchook GS; Fu S; Luthra R; Garrido-Laguna I; Kurzrock R
    PLoS One; 2011; 6(7):e22769. PubMed ID: 21829508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.
    Kaplan HG; Rostad S; Ross JS; Ali SM; Millis SZ
    J Natl Compr Canc Netw; 2018 Aug; 16(8):967-974. PubMed ID: 30099373
    [No Abstract]   [Full Text] [Related]  

  • 6. Sequence analysis of RAS and RAF mutation hot spots in canine carcinoma.
    Mochizuki H; Breen M
    Vet Comp Oncol; 2017 Dec; 15(4):1598-1605. PubMed ID: 27714944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features.
    Harada K; Hiraoka S; Kato J; Horii J; Fujita H; Sakaguchi K; Shiratori Y
    Br J Cancer; 2007 Nov; 97(10):1425-31. PubMed ID: 17923875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A molecular signature for oncogenic BRAF in human colon cancer cells is revealed by microarray analysis.
    Joyce T; Oikonomou E; Kosmidou V; Makrodouli E; Bantounas I; Avlonitis S; Zografos G; Pintzas A
    Curr Cancer Drug Targets; 2012 Sep; 12(7):873-98. PubMed ID: 22515520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients.
    Ruffinelli JC; Santos Vivas C; Sanz-Pamplona R; Moreno V
    Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):65-79. PubMed ID: 32946312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
    Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
    Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
    Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
    Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent involvement of ras-signalling pathways in both polypoid-type and flat-type early-stage colorectal cancers.
    Noda H; Kato Y; Yoshikawa H; Arai M; Togashi K; Nagai H; Konishi F; Miki Y
    J Exp Clin Cancer Res; 2006 Jun; 25(2):235-42. PubMed ID: 16918136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study.
    Makrodouli E; Oikonomou E; Koc M; Andera L; Sasazuki T; Shirasawa S; Pintzas A
    Mol Cancer; 2011 Sep; 10():118. PubMed ID: 21943101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants.
    Post JB; Roodhart JML; Snippert HJG
    Trends Cancer; 2020 Feb; 6(2):111-129. PubMed ID: 32061302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.
    Platz A; Egyhazi S; Ringborg U; Hansson J
    Mol Oncol; 2008 Apr; 1(4):395-405. PubMed ID: 19383313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
    Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications.
    Sclafani F; Gullo G; Sheahan K; Crown J
    Crit Rev Oncol Hematol; 2013 Jul; 87(1):55-68. PubMed ID: 23246082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study.
    Naguib A; Mitrou PN; Gay LJ; Cooke JC; Luben RN; Ball RY; McTaggart A; Arends MJ; Rodwell SA
    BMC Cancer; 2010 Mar; 10():99. PubMed ID: 20233436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
    Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
    Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct sets of genetic alterations in melanoma.
    Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
    N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.